BETA Technologies launches IPO of 25 million shares priced $27-$33
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Chief Medical Officer Jared Gollob, reported selling 3,114 shares of common stock at $60 on October 13, 2025, for a total of $186,840. The sale occurred near the stock’s 52-week high, with KYMR shares showing remarkable momentum, gaining over 135% in the past six months. According to InvestingPro analysis, technical indicators suggest the stock is currently in overbought territory.
On the same day, Gollob also exercised options to acquire a total of 1,473 shares of Kymera Therapeutics’ common stock. These transactions involved two separate option exercises with prices of $1.31 and $2.08, resulting in a total value of $2,447. With a market capitalization of $4.17 billion and its next earnings report scheduled for October 30, investors seeking deeper insights can access comprehensive analysis and 13 additional ProTips through InvestingPro’s detailed research report.
In other recent news, Kymera Therapeutics has been the focus of several analyst updates. Stifel has maintained its Buy rating on the company’s stock ahead of key data from a Phase 1b study for KT-621, a STAT6-degrader for atopic dermatitis. Truist Securities raised its price target for Kymera to $68, citing the potential of KT-621 and projecting approximately $1.9 billion in peak adjusted sales for the program. H.C. Wainwright also increased its price target to $70 after Kymera presented comprehensive data at EADV 2025. Barclays initiated coverage with an Overweight rating and a $60 price target, noting encouraging early clinical data for KT-621. Additionally, RBC Capital initiated coverage with an Outperform rating and a $70 price target, expressing confidence in the drug’s potential based on early proof of concept. These developments highlight the growing interest in Kymera’s KT-621 program among analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.